Kinzel Adrian, Ambrogi Michael, Varshaver Michael, Kirson Eilon D
Novocure GmbH, Munich, Germany.
Novocure Inc, Portsmouth, NH, USA.
Clin Med Insights Oncol. 2019 Jan 29;13:1179554918825449. doi: 10.1177/1179554918825449. eCollection 2019.
Tumor treating fields (TTFields) are a non-invasive antimitotic therapy that delivers alternating electric fields via the Optune system. The Phase III EF-14 trial in newly diagnosed glioblastoma multiforme (GBM) showed significantly improved progression-free, overall and long-term survival when Optune was used together with maintenance temozolomide (TMZ) compared with TMZ alone. Compliance (average monthly use) was associated with better clinical outcome. The first-generation Optune system weighed approximately 6 pounds (2.7 kg). The second-generation redesigned Optune system weighs 2.7 pounds (1.2 kg). We tested and compared GBM patient experience with the second-generation system versus the first-generation system.
Ten newly diagnosed and recurrent GBM patients in Germany (median age: 52.9 years [31-79]) were prospectively monitored over the first month of transitioning from the first-generation to the second-generation Optune system. Questionnaires using a numerical analog scale assessed feedback at baseline (first generation) and after 1 month of second-generation use.
After transitioning to the second-generation system, compliance improved by more than 10% in four patients, was maintained in five patients and decreased by more than 10% in one patient. Following transition, eight out of nine patients reported a reduction in the triggering of malfunction alarms. Self-reported patient feedback showed improved handling and portability (weight, mobility) of the second- versus the first-generation Optune system.
This patient user survey suggests that patient satisfaction with the second-generation Optune system is improved versus the first-generation system. Improved features of the new system help patients achieve and maintain a higher rate of treatment compliance.
肿瘤治疗电场（TTFields）是一种非侵入性抗有丝分裂疗法，通过Optune系统输送交变电场。针对新诊断的多形性胶质母细胞瘤（GBM）的III期EF-14试验表明，与单独使用替莫唑胺（TMZ）相比，Optune与维持性替莫唑胺（TMZ）联合使用时，无进展生存期、总生存期和长期生存期均有显著改善。依从性（平均每月使用量）与更好的临床结果相关。第一代Optune系统重约6磅（约2.7千克）。第二代重新设计的Optune系统重2.7磅（约1.2千克）。我们测试并比较了GBM患者使用第二代系统与第一代系统的体验。
对德国10例新诊断和复发性GBM患者（中位年龄：52.9岁[31-79岁]）从第一代Optune系统过渡到第二代系统的第一个月进行前瞻性监测。使用数字模拟量表的问卷在基线（第一代）和第二代使用1个月后评估反馈。
过渡到第二代系统后，4例患者的依从性提高了10%以上，5例患者的依从性保持不变，1例患者的依从性下降了10%以上。过渡后，9例患者中有8例报告故障警报触发次数减少。患者自我报告的反馈显示，与第一代Optune系统相比，第二代系统的操作性和便携性（重量、移动性）有所改善。
这项患者用户调查表明，与第一代系统相比，患者对第二代Optune系统的满意度有所提高。新系统改进的功能有助于患者实现并维持更高的治疗依从率。
